STRIDES PHARMA Q2 : CONS NET PROFIT UP 2% AT 134 CR (YOY), DOWN 19% (QOQ). MIX (On 1st Look)

Revenue up 17.1% at ₹1,429.7 Cr (YOY), up 13.0% (QOQ). Ebitda down 1.4% at ₹255 Cr (YOY), up 8.7% (QOQ); margins 17.8% v 21.2% (YOY), 18.5% (QOQ). Profit before exceptional items and tax down 7.2% at ₹151.2 Cr (YOY); H1 revenue ₹2,695.1 Cr v ₹2,340.6 Cr. Caution: Q1 FY27 had a ₹74.2 Cr one-time gain on loss of control of Pivot Path (stake cut to 19.95%), inflating the QOQ base; Q2 had ₹1.7 Cr recall/settlement expense.

Strides Pharma Science Limited

Open attachment

← Back to feed